DALLAS, June 27,
2024 /PRNewswire/ -- Jacobs (NYSE:J) was
selected by FUJIFILM Diosynth Biotechnologies to support delivery
of $1.2 billion expansion of an
end-to-end, large-scale cell culture contract manufacturing site in
Holly Springs, North Carolina.
Jacobs was originally selected to support the construction for the
FUJIFILM Diosynth Biotechnologies' Holly
Springs site, which broke ground in 2021. Jacobs will
provide engineering, procurement and construction management
services for the site's latest expansion.
"This expansion of the project at Holly Springs is testament to the relationship
of trust and accountability Jacobs and FUJIFILM Diosynth
Biotechnologies have built," said Jacobs Senior Vice
President Koti Vadlamudi. "Together
we'll continue to leverage digital innovation and modular design so
that medicines and therapies are delivered with quality,
flexibility, speed and consistency—now at an even larger
scale."
The expansion will leverage the existing engineering and
facility designs, with an additional 8 x 20,000 liter (L) cell
culture bioreactors and approximately 400,000 square feet of
manufacturing space by 2028, to the already planned 8 x 20,000 L
for bulk drug substance as part of the initial investment. The
first phase of construction is planned for completion in 2025.
"Once complete, the site will be one of the largest, end-to-end
cell culture contract manufacturing facilities in North America," said FUJIFILM Diosynth
Biotechnologies COO and Executive Vice President of Operations
Kenneth Bilenberg. "Leveraging our
KojoXTM philosophy, the project will significantly
increase FUJIFILM Diosynth Biotechnologies' manufacturing capacity
for biologic therapeutics and medicines for patients globally. The
site will provide drug substance manufacturing, automated
fill-finish and assembly, packaging and labeling services for
global biopharmaceutical customers."
At Jacobs, we're challenging today to reinvent tomorrow by
solving the world's most critical problems for thriving cities,
resilient environments, mission-critical outcomes, operational
advancement, scientific discovery and cutting-edge manufacturing,
turning abstract ideas into realities that transform the world for
good. With approximately $16 billion
in annual revenue and a talent force of more than 60,000, Jacobs
provides a full spectrum of professional services including
consulting, technical, scientific and project delivery for the
government and private sector. Visit jacobs.com and
connect with Jacobs on Facebook, Instagram, LinkedIn and
X.
Certain statements contained in this press release constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are statements that do not directly relate to any
historical or current fact. When used herein, words such as
"expects," "anticipates," "believes," "seeks," "estimates,"
"plans," "intends," "future," "will," "would," "could," "can,"
"may," and similar words are intended to identify forward-looking
statements. We base these forward-looking statements on
management's current estimates and expectations, as well as
currently available competitive, financial and economic data.
Forward-looking statements, however, are inherently uncertain.
There are a variety of factors that could cause business results to
differ materially from our forward-looking statements including,
but not limited to, our plans to spin off and merge
with Amentum our Critical Missions Solutions business
and a portion of our Divergent Solutions business in a proposed
transaction that is intended to be tax-free to stockholders for
U.S. federal income tax purposes, the timing of the award of
projects and funding and potential changes to the amounts provided
for under the Infrastructure Investment and Jobs Act and other
legislation related to governmental spending, as well as general
economic conditions, including inflation and the actions taken by
monetary authorities in response to inflation, changes in interest
rates and foreign currency exchange rates, changes in capital
markets, the possibility of a recession or economic downturn,
geopolitical events and conflicts, and the impact of any future
pandemic or infectious disease outbreak, including the related
reaction of governments on global and regional market conditions,
among others. For a description of some additional factors that may
occur that could cause actual results to differ from our
forward-looking statements, see the discussions contained under
Item 1 - Business; Item 1A - Risk Factors; Item 3 - Legal
Proceedings; and Item 7 - Management's Discussion and Analysis of
Financial Condition and Results of Operations in our most recently
filed Annual Report on Form 10-K, and Item 2 - Management's
Discussion and Analysis of Financial Condition and Results of
Operations; Item 1 - Legal Proceedings; and Item 1A - Risk Factors
in our most recently filed Quarterly Report on Form 10-Q, as well
as the company's other filings with the Securities and Exchange
Commission. The company is not under any duty to update any of the
forward-looking statements after the date of this press release to
conform to actual results, except as required by applicable
law.
For press/media inquiries:
media@jacobs.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/jacobs-selected-to-support-delivery-of-1-2b-expansion-of-fujifilm-diosynth-biotechnologies-large-scale-biologics-manufacturing-site-302182916.html
SOURCE Jacobs